Package Leaflet: Information for the User
Movymia 20 micrograms/80 microliters solution for injection
Teriparatide
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Movymia contains the active substance teriparatide, which is used to increase bone strength and reduce the risk of fractures by stimulating bone formation.
Movymia is used for the treatment of osteoporosis in adults. Osteoporosis is a disease that makes your bones wear down and become fragile. This disease is especially common in women after menopause, but it can also occur in men. Osteoporosis is also common in patients treated with medicines called corticosteroids.
Do not use Movymia
Warnings and precautions
Movymia may increase calcium in your blood or urine.
Talk to your doctor before or while using Movymia:
Some patients, after the first doses of Movymia, experience dizziness or an increase in heart rate. For the first doses, use Movymia in a place where you can sit or lie down immediately if you feel dizzy.
The recommended treatment time of 24 months should not be exceeded.
Before inserting a cartridge into the Movymia Pen, note the batch number (Batch) of the cartridge and the date of the first injection on the cartridge box and provide this information when reporting any adverse reaction.
Movymia should not be used in adults who are still growing.
Children and adolescents
Movymia should not be used in children and adolescents (under 18 years of age).
Other medicines and Movymia
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
This is important because some medicines (e.g., digoxin/digitals, a medicine used to treat heart diseases) may interact with teriparatide.
Pregnancy and breastfeeding
Do not use Movymia if you are pregnant or breastfeeding. If you are a woman of childbearing age, you should use effective contraceptive methods during treatment with Movymia. If you become pregnant while using Movymia, treatment should be discontinued. Consult your doctor or pharmacist before using this medicine.
Driving and using machines
Some patients may feel dizzy after the injection of Movymia. If you feel dizzy, do not drive or use machines until you feel better.
Movymia contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose unit, which is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
The recommended dose is 20 micrograms (corresponding to 80 microliters) administered once a day by subcutaneous injection in the thigh or abdomen.
To help you remember to inject your medicine, inject it at the same time every day.
Movymia can be injected at mealtime. Inject Movymia every day for as long as your doctor prescribes it. The total duration of treatment with Movymia should not exceed 24 months. You should not receive more than one 24-month treatment cycle in your lifetime.
Your doctor may advise you to use Movymia with calcium and vitamin D. Your doctor will tell you how much to take each day.
Movymia can be administered with or without food.
The Movymia cartridges are designed for use exclusively with the reusable Movymia Pen multidose administration system and compatible pen needles. The pen and needles are not included with Movymia. However, for the start of treatment, a pack with a cartridge and pen should be used, which contains a cartridge case and a Movymia Pen case.
The pen can be used with injection needles developed according to the ISO standard for pen needles with a gauge between 29 G and 31 G (diameter of 0.25 - 0.33 mm) and a length between 5 mm and 12.7 mm only for subcutaneous injection.
Before the first use, insert the cartridge into the pen. To use this medicine correctly, it is very important that you follow the detailed instructions for use of the pen provided with it.
Use a new injection needle for each injection to prevent contamination and dispose of the needle safely after use.
Never store the pen with the needle attached.
Never share your pen with others.
Do not use the Movymia Pen to inject any other medicine (e.g., insulin). The pen is designed for use with Movymia only.
Do not refill the cartridge.
Do not transfer the medicine to a syringe.
You should inject Movymia shortly after removing the pen with the cartridge inserted from the refrigerator. Put the pen with the cartridge inserted back in the refrigerator immediately after use. Do not remove the cartridge from the pen after each use. Keep it in the cartridge holder for the complete 28-day treatment period.
Preparing the pen for use
Make sure there are at least 28 days left until the expiration date. Insert the cartridge into the pen before the first use as detailed in the pen instructions. Note the batch number (Batch) of each cartridge and the first injection date on a calendar.
You should also note the first injection date on the Movymia carton (see the space provided on the box: {First use:}).
Injecting Movymia
If you use more Movymia than you should
If you have accidentally administered more Movymia than prescribed, talk to your doctor or pharmacist.
The effects that can be expected from an overdose include nausea, vomiting, dizziness, and headache.
If you forget to use Movymia
If you miss an injection or cannot inject your medicine at the usual time, do so as soon as possible on the same day. Do not use a double dose to make up for missed doses. Do not inject more than once on the same day.
If you stop using Movymia
If you are thinking of stopping treatment with Movymia, please consult your doctor. Your doctor will advise and decide how long you should be treated with Movymia.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most common side effects are pain in the limbs (very common, may affect more than 1 in 10 patients). Other common side effects (affecting up to 1 in 10 patients) are discomfort, headache, and dizziness. If you feel dizzy after an injection, sit or lie down until you feel better. If it does not improve, consult your doctor before continuing treatment. There have been cases of fainting after the use of teriparatide.
If you experience discomfort around the injection site such as redness of the skin, pain, swelling, itching, bruising, or slight bleeding (which can occur frequently), these should disappear within a few days or weeks. If not, tell your doctor.
Rare (may affect up to 1 in 1,000 patients), some patients may experience allergic reactions, which consist of difficulty breathing, swelling of the face, rash, and chest pain. These reactions usually occur shortly after the injection. In rare cases, severe and potentially life-threatening allergic reactions, including anaphylaxis, may occur.
Other side effects are:
Common(may affect up to 1 in 10 patients):
Uncommon(may affect up to 1 in 100 patients):
Rare(may affect up to 1 in 1,000 patients):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the pack and cartridge after CAD and EXP respectively. The expiration date is the last day of the month indicated.
Store in a refrigerator (between 2 °C and 8 °C). Do not freeze.
Keep the cartridge in the case to protect it from light.
You can use Movymia for 28 days after the first injection, provided the cartridge / pen with the cartridge inserted is stored in a refrigerator (between 2 °C and 8 °C).
Avoid placing the cartridge near the freezer compartment of the refrigerator to prevent freezing. Do not use Movymia if it has been frozen.
Each cartridge should be disposed of properly after 28 days of first use, even if it is not empty.
Movymia contains a clear and colorless solution. Do not use Movymia if it has solid particles or if the solution is cloudy or discolored.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Movymia Composition
Product Appearance and Container Contents
Movymia is a clear and colorless injectable solution. It is presented in a cartridge. Each cartridge contains 2.4 ml of solution sufficient for 28 doses.
Package sizes: 1 cartridge or 3 cartridges packaged in a sealed plastic tray with a lid and packaged in a box.
Package with cartridge and Movymia Pen: 1 Movymia cartridge packaged in a sealed plastic tray with a lid and packaged in a box, and 1 Movymia Pen packaged in a box.
Only some package sizes may be marketed.
Marketing Authorization Holder
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Manufacturer
Gedeon Richter Plc.
Gyömroi út 19-21.
1103 Budapest
Hungary
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Laboratorio STADA, S.L.
Phone: +34 934738889
Date of Last Revision of this Leaflet:September 2021.
Other Sources of Information
Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu/
Detailed information on this product is also available by scanning the QR code below or the box with a smartphone. The same information is also available at the following URL: movymiapatients.com
Instructions for Use
Movymia Pen
Reusable injection pen for use with Movymia cartridges, for subcutaneous injection
When using the Movymia Pen, always follow the instructions given below and on the back.
Parts of the Movymia Pen
Preparing the Pen - First Use / Cartridge Change
Follow the instructions each time you insert a new Movymia cartridge into the Movymia Pen. Do not repeat this step before each daily injection, as you will not have enough Movymia for 28 days.
Read the Movymia cartridge leaflet provided separately.
A: Remove the pen cap.
B: Turn the cartridge holder to remove it (bayonet fitting).
C: If you want to change the cartridge, remove the empty cartridge. Place a new Movymia cartridge in the cartridge holder with the cartridge's metal foldable cap first.
Record the date of the first injection of each new cartridge. This will help you know when the 28 daily doses per cartridge are finished.
D: Carefully push the threaded rod straight in with your finger until it stops. This is not necessary when the rod is already in the initial position, such as the first time it is used. The threaded rod cannot be fully inserted into the pen casing.
E: Attach the cartridge holder to the pen casing by turning it 90 degrees until it stops.
F: Attach a new pen needle as follows:
When attaching the needle, a few drops may escape; this is normal.
G: Priming
The pen must be primed and tested before inserting a new cartridge and before the first injection of each cartridge.
If not, repeat step G until you see some drops. Do not repeat step G more than four times; if necessary, follow the instructions in the Troubleshooting section on the back.
Administration using the Movymia Pen
Wash your hands carefully with soap to reduce the risk of infection.
Make sure you have:
Do not usethe pen if the cartridge is cloudy or colored or contains particles.
Read the Movymia cartridge leaflet provided separately.
Use a new needle for each injection. Do not use the pen needle if the packaging is damaged or you did not open it.
Note:it is not necessary to change the needle when using immediately after preparing the pen. In this case, continue with the "2. Dose adjustment and injection" step.
When attaching the needle, a few drops may escape; this is normal.
Warning: make sure to use the correct medication liquid. Check the cartridge label before inserting it into the cartridge holder.
Note:if the cartridge contains less than 80 microliters, the dose button cannot be turned clockwise to the arrow symbol. In this case, remove the pen cap, change the cartridge, and perform a priming following the pen preparation steps.
Warning:avoid bending or breaking the pen needle. Do not tilt the pen after inserting the needle into the skin. Tilt the pen can bend or break the needle. Broken needles can remain stuck in the skin. If a broken needle remains stuck in the skin, consult a doctor immediately.
Note for Healthcare Professionals
Local, healthcare professional, or institutional policies may replace the instructions regarding needle handling and disposal.
Additional Information
The reusable fixed-dose pen is designed for easy administration of Movymia to treat osteoporosis. Each Movymia cartridge contains 28 fixed doses of 80 microliters of Movymia.
Use the Movymia Pen only as directed by your doctor and according to the information in these instructions for use and the Movymia leaflet.
The Movymia Pen can be used by patients who self-inject and are over 18 years old, healthcare professionals, or third parties such as adult family members.
The Movymia Pen should not be used by blind or visually impaired patients without the help of a physically able person who is properly trained. Consult your doctor if you have hearing or handling problems.
If you have any questions about using the Movymia Pen, contact our customer serviceat any time.
Phone number: XXXXXXXXXXX
Email: XXXXXXXXXXX
Pen-compatible Needles
Pen needles from other manufacturers may be used in accordance with the compatibility details indicated.
Pen needles must be used only onceand only one person should use the Movymia cartridge.
Storage and Care of the Movymia Pen
How to Dispose of the Movymia Pen and Used Accessories
The Movymia Pen has a lifespan of two years. Before disposing of the Movymia Pen, remove the needle and cartridge. Used needles and cartridges must be disposed of safely and separately. The Movymia Pen can be disposed of in accordance with local authority instructions.
Warnings
Follow the instructions presented in these instructions for use. If these instructions are not followed, there is a risk of medication errors, inadequate dosing, disease transmission, or infection. If you have any health problems, seek medical attention immediately.
Warranty
The warranty covers material and manufacturing defects of the Movymia Pen for two years of use from the date of purchase. It is limited to replacing the pen. The warranty does not cover damage caused by:
Troubleshooting
If you have any questions about using the Movymia Pen, follow the instructions given in the table on the next page:
Question | Answer |
| A small air bubble will not affect the dose or cause damage. |
| Use another needle. If the second needle cannot be placed, contact the customer service. |
| Use another needle. |
| Do not use that pen; contact the customer service. |
| Change the needle and repeat the priming as indicated in the pen preparation sections "F" and "G". If medication still does not come out, do not use that pen; contact the customer service. |
| The amount of Movymia remaining in the cartridge is less than 80 microliters. Change the cartridge and pen needle and perform a priming in accordance with the pen preparation steps. |
| Do not repeat the injection on the same day. Use a new needle for the injection the next day. Adjust the dose and perform the injection as described in the "2. Dose adjustment and injection" section. If the dose indicator still does not return to the initial position after injection, do not use that pen; contact the customer service. |
| Do not use that pen; contact the customer service. |
How can I reset the dose button to the initial position? | Do not press the pusher. To reset the pen, simply turn the dose button counterclockwise to the initial position. |
Distributor:
XXXXXXXXXX
Importer:
Gedeon Richter Plc.
Gyömroi út 19-21
1103 Budapest
Hungary
Authorized Representative in the European Community:
Ypsomed Distribution GmbH
Warmbacher Strasse 80
79618 Rheinfelden
Germany
Legal Manufacturer:
Ypsomed AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
CE 0123
Date of text revision: